Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study

2018 ◽  
Vol 25 (11) ◽  
pp. 1298-1305 ◽  
Author(s):  
R. Flisiak ◽  
E. Janczewska ◽  
M. Łucejko ◽  
E. Karpińska ◽  
D. Zarębska-Michaluk ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Function ◽  
Real World ◽  
De Novo ◽  
Virologic Response ◽  
De Novo Hepatocellular Carcinoma

Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response

2019 ◽  
Vol 39 (11) ◽  
pp. 2174-2183 ◽  
Author(s):  
Victoria T. Mücke ◽  
Dominique Thomas ◽  
Marcus M. Mücke ◽  
Oliver Waidmann ◽  
Stefan Zeuzem ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Sustained Virologic Response ◽  
De Novo ◽  
Virologic Response ◽  
Cirrhotic Patients ◽  
De Novo Hepatocellular Carcinoma

scholarly journals Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response

2021 ◽  
Author(s):  
Hidenori Toyoda ◽  
Atsushi Hiraoka ◽  
Haruki Uojima ◽  
Akito Nozaki ◽  
Noritomo Shimada ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Sustained Virologic Response ◽  
De Novo ◽  
Virologic Response ◽  
De Novo Hepatocellular Carcinoma

Unresectable hepatocellular carcinoma: prospects for drug therapy with lenvatinib

2022 ◽  
Vol 11 (3) ◽  
pp. 45-52
Author(s):  
V.  V. Breder ◽  
D.  T. Abdurakhmanov ◽  
V.  V. Petkau ◽  
P.  V. Balakhnin ◽  
M.  V. Volkonsky ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Drug Therapy ◽  
Liver Function ◽  
Real World ◽  
Systemic Therapy ◽  
Efficacy And Safety ◽  
Study Results ◽  
Class B ◽  
Pugh Class ◽  
Positive Results

There is a number of unresolved issues regarding the systemic therapy administration for hepatocellular carcinoma (HCC). Their solution is facilitated by accumulating real‑world study results. Lenvatinib therapy is a recognized drug with a good efficacy and safety profile for the treatment of HCC. Subanalyses of the REFLECT study showed that the absence of stratification by baseline AFP and baseline liver function, as well as the lack of options for subsequent drug therapy after lenvatinib, also affects the outcomes. Once these factors are taken into account, the hypothesis of superiority of lenvatinib to sorafenib and other drugs can be tested. Real‑world clinical studies have demonstrated positive results of lenvatinib therapy in patients with Child‑Pugh class B liver function, provided recommendations on the sequence of systemic therapy after lenvatinib and on the use of lenvatinib in patients with BCLC stage B, along with considering the possibility of lenvatinib monotherapy and the prospects for its use in patients with nHCC. Further real‑world studies of lenvatinib for HCC in the Russian population are required.

A genetic risk score predicts de novo hepatocellular carcinoma in hepatitis C cirrotic patients treated with direct-acting antivirals

2020 ◽  
Vol 73 ◽  
pp. S208-S209
Author(s):  
Elisabetta Degasperi ◽  
Enrico Galmozzi ◽  
Serena Pelusi ◽  
Roberta D’ambrosio ◽  
Roberta Soffredini ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Risk Score ◽  
Genetic Risk ◽  
De Novo ◽  
Genetic Risk Score ◽  
Direct Acting Antivirals ◽  
Direct Acting ◽  
De Novo Hepatocellular Carcinoma

De novo hepatocellular carcinoma post-multivisceral transplantation in a child

2017 ◽  
Vol 21 (7) ◽  
pp. e12991 ◽  
Author(s):  
P. Tran ◽  
S. Zhou ◽  
L. Wang ◽  
M. Finegold ◽  
L. Mascarenas ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
De Novo ◽  
Multivisceral Transplantation ◽  
De Novo Hepatocellular Carcinoma
Sign in / Sign up

Export Citation Format

Share Document